2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
195
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
18
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Interventions
Levetiracetam
6
Cannabidiol
5
perampanel
2
Tranexamic Acid
2
Standard of Care
2
Everolimus
2
ziprasidone
1
enzalutamide
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tobramycin
1
Temozolomide
1
Spironolactone
1
Solutions
1
Sodium Chloride
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Remifentanil
1
Propofol
1
Pregabalin
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Seizures
×
enzalutamide
×
Clear all
NCT01977651
2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4
Completed
424 enrolled
10 charts